SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
暂无分享,去创建一个
G. Herrler | M. Müller | C. Drosten | M. Hoffmann | S. Pöhlmann | N. Wu | Hannah Kleine-Weber | Simon Schroeder | Nadine Krüger | T. Herrler | Sandra Erichsen | T. Schiergens | A. Nitsche | S. Schroeder
[1] Kai Zhao,et al. Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[2] L. Garmire,et al. Prediction of repurposed drugs for treating lung injury in COVID-19 , 2020, F1000Research.
[3] H. Nishisaki,et al. Humidifier Use and Prone Positioning in a Patient with Severe COVID-19 Pneumonia and Endotracheal Tube Impaction Due to Highly Viscous Sputum , 2020, Cureus.
[4] The “Three Italy” of the COVID-19 epidemic and the possible involvement of SARS-CoV-2 in triggering complications other than pneumonia , 2020, Journal of NeuroVirology.
[5] A. Basu,et al. Faculty Opinions recommendation of SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[6] Jianping Li,et al. Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019 , 2020, Chronic Diseases and Translational Medicine.
[7] A. Barabasi,et al. Network medicine framework for identifying drug-repurposing opportunities for COVID-19 , 2020, Proceedings of the National Academy of Sciences.
[8] P. Horby,et al. A novel coronavirus outbreak of global health concern , 2020, The Lancet.
[9] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[10] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[11] M. Koopmans,et al. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. , 2020, The New England journal of medicine.
[12] S. Lo,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.
[13] Victor M Corman,et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[14] Lisa E. Gralinski,et al. Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection , 2019, Journal of Virology.
[15] A. Walls,et al. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors , 2019, Nature Structural & Molecular Biology.
[16] V. Corman,et al. Coronaviren als Ursache respiratorischer Infektionen , 2019, Der Internist.
[17] Yukiko Shimizu,et al. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection , 2019, Journal of Virology.
[18] M. Hoffmann,et al. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein , 2018, Scientific Reports.
[19] B. Graham,et al. Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization , 2018, Journal of Virology.
[20] Sudhir Kumar,et al. MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. , 2018, Molecular biology and evolution.
[21] K. Shirato,et al. Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry , 2017, Virology.
[22] Inga Nehlmeier,et al. The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells , 2017, PloS one.
[23] M. Tortorici,et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein , 2017, Proceedings of the National Academy of Sciences.
[24] S. Perlman,et al. Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. , 2017, Annual review of medicine.
[25] W. Baumgärtner,et al. The differentiated airway epithelium infected by influenza viruses maintains the barrier function despite a dramatic loss of ciliated cells , 2016, Scientific Reports.
[26] K. Shirato,et al. Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry , 2016, Journal of Virology.
[27] S. Perlman,et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism , 2016, Proceedings of the National Academy of Sciences.
[28] Makoto Takeda,et al. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay , 2016, Antimicrobial Agents and Chemotherapy.
[29] D. Falzarano,et al. SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.
[30] R. Baric,et al. Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus , 2015, Journal of Virology.
[31] Yanchen Zhou,et al. Protease inhibitors targeting coronavirus and filovirus entry , 2015, Antiviral Research.
[32] R. Baric,et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus , 2014, Proceedings of the National Academy of Sciences.
[33] J. Epstein,et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor , 2013, Nature.
[34] C. Schwegmann-Wessels,et al. Differential Sensitivity of Bat Cells to Infection by Enveloped RNA Viruses: Coronaviruses, Paramyxoviruses, Filoviruses, and Influenza Viruses , 2013, PloS one.
[35] Christian Drosten,et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.
[36] Christian Drosten,et al. The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies , 2013, Journal of Virology.
[37] U. Buchholz,et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[38] P. Nelson,et al. Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts , 2012, PloS one.
[39] L. van der Hoek,et al. Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry , 2012, Journal of Virology.
[40] G. Zimmer,et al. A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon , 2011, PloS one.
[41] Christian Drosten,et al. Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response , 2011, Journal of Virology.
[42] Jincun Zhao,et al. A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry , 2010, Journal of Virology.
[43] Makoto Takeda,et al. Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2 , 2010, Journal of Virology.
[44] K. Schughart,et al. TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells , 2010, Journal of Virology.
[45] T. Sasazuki,et al. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry , 2008, Proceedings of the National Academy of Sciences.
[46] Yan Liu,et al. Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine , 2007, Antiviral therapy.
[47] Shibo Jiang,et al. Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design , 2006, Journal of Virology.
[48] Wei Liu,et al. Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome , 2006, The Journal of infectious diseases.
[49] P. Nelson,et al. Phenotypic Analysis of Mice Lacking the Tmprss2-Encoded Protease , 2006, Molecular and Cellular Biology.
[50] Kwok-Hung Chan,et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[51] S. Harrison,et al. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.
[52] S. Diamond,et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[53] Bo Zhang,et al. Multiple organ infection and the pathogenesis of SARS , 2005, The Journal of experimental medicine.
[54] Mark Chappell,et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.
[55] Arthur S Slutsky,et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.
[56] Ben Berkhout,et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[57] Chengsheng Zhang,et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 , 2005, The EMBO journal.
[58] Michelle M. Packard,et al. Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan , 2005, Human Pathology.
[59] K. Überla,et al. S Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing Antibodies in Infected Patients , 2004, Journal of Virology.
[60] G. Fey,et al. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor , 2004, Biochemical and Biophysical Research Communications.
[61] Qingling Zhang,et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.
[62] G. Navis,et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.
[63] X. L. Liu,et al. Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.
[64] Lin-Fa Wang,et al. Membrane Fusion Tropism and Heterotypic Functional Activities of the Nipah Virus and Hendra Virus Envelope Glycoproteins , 2002, Journal of Virology.
[65] A. Look,et al. Human aminopeptidase N is a receptor for human coronavirus 229E , 1992, Nature.